[[Arotinolol]]

CATEGORIES: Beta blockers, Amides, Thiophenes, Thiazoles, Thioethers, Alcohols, Amines

Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers.[tpl]cite journal |author=Zhao |title=Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes |journal=Can J Physiol Pharmacol |volume=79 |issue=7 |pages=585–593 |date=July 2001 |pmid=11478592 |doi= 10.1139/cjpp-79-7-585|url=http://article.pubs.nrc-cnrc.gc.ca/ppv/RPViewDoc?issn=0008-4212&volume=79&issue=7&startPage=585|first = Jin|first2 = Valeria|last2 = Golozoubova|first3 = Barbara|last3 = Cannon|first4 = Jan|last4 = Nedergaard[/tpl][tpl]Closed access[/tpl]  A 1979 publication suggests arotinolol as having first been described in the scientific literature by Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".[tpl]Cite journal|title = 新しいβ-受容体遮断薬，dl-2-(3'-t-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)-thiazole hydrochloride (S-596) の薬理作用|year = 1979|url = https://www.jstage.jst.go.jp/article/fpj1944/75/7/75_7_707/_article|first = Youichi|last = Hara|last2 = Sato|first2 = Etsuro|first3 = Akira|last3 = Miyagishi|first4 = Shunzi|last4 = Aono|first5 = Hiroshi|last5 = Nakatani|journal = Folia Pharmacologica Japonica|doi = 10.1254/fpj.75.707|issn = 1347-8397|pages = 707-720|language = Japanese (English abstract)|trans_title = Pharmacological properties of dl-2-(3'-t-butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochloride (S-596), a new β-adrenergic blocking agent[/tpl][tpl]Open access[/tpl]

==Uses==

It is used in the treatment of high blood pressure.[tpl]cite journal |author=Wu |title=Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers |journal=Hypertension Research |volume=24 |issue=5 |pages=605–10 |date=September 2001 |pmid=11675958 |doi= 10.1291/hypres.24.605|url=https://www.jstage.jst.go.jp/article/hypres/24/5/24_5_605/_pdf |format=PDF|issn = 1348-4214|first = Haiying|last2 = Zhang|first2 = Yuqing|first3 = Jianfeng|last3 = Huang|last4 = Zhang|first4 = Yuhui|last5 = Liu|first5 = Guozhang|last6 = Sun|first6 = Ningling|last7 = Yu|first7 = Zhenqui|last8 = Zhou|first8 = Yanrong[/tpl][tpl]Open access[/tpl]
It has been proposed for use in treatment of essential tremor.[tpl]cite journal |author=Lee |title=A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor |journal=Parkinsonism & Related Disorders |volume=9 |issue=6 |pages=341–347 |date=August 2003 |pmid=12853233 |doi= 10.1016/S1353-8020(03)00029-4|url=http://download.journals.elsevierhealth.com/pdfs/journals/1353-8020/PIIS1353802003000294.pdf|first = Kwang-Soo|first2 = Joong-Seok|last2 = Kim|first3 = Jae-Woo|last3 = Kim|first4 = Won-Yong|last4 = Lee|first5 = Beum-Seok|last5 = Jeon|first6 = Dongjae|last6 = Kim[/tpl][tpl]Closed access[/tpl]
Recommended dosage 10 - 30 mg

==References==

==External links==

http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=92

